The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the accelerating consolidation within the biotech sector to enhance analytical capabilities, 10x Genomics has announced the acquisition of Proteintech Genomics. According to reports, the acquired division specializes in high-plex proteomic solutions. The acquisition aims to integrate Proteintech’s technology into 10x platforms to accelerate scientific research and advancements in human health.
This strategic move comes as the proteomics market experiences significant growth, with companies racing to provide integrated solutions that combine genomic and proteomic analysis. Compared to peers, 10x Genomics is positioning itself to capture a larger share of the spatial biology market against competitors like Illumina and NanoString. Per market data, this acquisition strengthens the company's footprint in the high-demand single-cell analysis segment used by global research institutions.
Sign in to access this content
Sign InRegarding market performance, TXG stock closed at $29.05 (close June 11, 2026), trading between a high of $29.62 and a low of $28.01 during the session. Investors are now watching for further financial details regarding the transaction and its impact on future cash flows. On the economic calendar, traders are looking ahead to French Balance of Trade and Eurozone Industrial Production data later today for broader market sentiment cues.